«上一篇/Previous Article|本期目录/Table of Contents|下一篇/Next Article»

《天津医科大学学报》[ISSN:1006-8147/CN:12-1259/R]

卷:

30卷

期数:

2024年03期

页码:

245-249

栏目:

临床医学

出版日期:

2024-05-20

文章信息/Info

Title:

Effect of acupuncture and moxibustion combined with tirofiban on patients with acute progressive cerebral infarction

文章编号:

1006-8147(2024)03-0245-05

作者:

刘勇¹; 3; 张美云²; 胡冠群²; 刘玲凤²

（1.天津医科大学人民医院临床学院，天津 300070；2.天津市人民医院神经内科，天津 300121；3.河北医科大学附属沧州中西医结合医院神经内科，沧州 061000）

Author(s):

LIU Yong¹; 3;  ZHANG Mei yun²;  HU Guanqun²;  LIU Lingfeng²

（1.People′s Hospital Clinical School， Tianjin Medical University， Tianjin 300070， China； 2.Department of Neurology， Tianjin Union Medical Center， Tianjin 300121， China； 3.Department of Neurology， Cangzhou Hospital of Integrated Traditional Chinese and Western Medicine Affiliated to Hebei Medical University， Cangzhou 061000， China）

关键词:

针灸; 替罗非班; 急性进展性脑梗死; 神经功能; 血液流变学

Keywords:

acupuncture and moxibustion;  tirofiban;  acute progressive cerebral infarction;  neurological function;  hemorheology

分类号:

R277.7

DOI:

10.20135/j.issn.1006-8147.2024.03.0245

文献标志码:

A

摘要:

目的：分析针灸联合替罗非班对急性进展性脑梗死的疗效。方法：收集2022年8月至2023年7月来天津市人民医院神经内科就诊的114例急性进展性脑梗死患者为研究对象，采用随机对照研究，按随机数字表法分为联合组和对照组，每组57例；对照组给予阿司匹林联合氯吡格雷“双抗”治疗，联合组给予阿司匹林联合氯吡格雷“双抗”治疗+替罗非班联合针灸治疗；记录并比较两组患者临床疗效、美国国立卫生研究院卒中量表（NIHSS）评分、简易智能精神状态检查量表（MMSE）评分、血液流变学指标水平及不良反应。结果： 联合组临床总有效率为85.96%（49/57），对照组临床总有效率为68.42%（39/57），联合组显著高于对照组（P<0.05）；第7天，联合组NIHSS评分显著低于对照组（P<0.05），MMSE评分与对照组相比无差异（P>0.05）；第14天，联合组NIHSS评分显著低于对照组，MMSE评分显著高于对照组（P<0.05）；与治疗前相比，第7天和第14天两组NIHSS评分依次显著降低，MMSE评分依次显著升高（均P<0.05）。第7天和第14天，联合组全血高切黏度、全血低切黏度、血浆黏度、红细胞电泳时间均显著低于对照组（均P<0.05）。与治疗前相比，第7天和第14天两组全血高切黏度、全血低切黏度、血浆黏度、红细胞电泳时间均依次显著降低（均P<0.05）。联合组不良反应总发生率为8.77%，对照组为12.28%，两组之间比较差异无统计学意义（P>0.05）。结论：针灸联合替罗非班治疗急性进展性脑梗死患者的疗效显著，有效降低了NIHSS评分，提高了MMSE评分，并改善患者血液流变学指标，用药安全性高。

Abstract:

Objective： To analyze the impacts of acupuncture and moxibustion combined with tirofiban on patients with acute progressive cerebral infarction. Methods： A total of 114 patients with acute progressive cerebral infarction who visited the Department of Neurology， Tianjin Union Medical Center from August 2022 to July 2023 were enrolled in this study. A randomized single blind controlled study was conducted. They were divided into a combination group and a control group using a random number table method， with 57 cases in each group. The control group was given aspirin combined with clopidogrel "dual antiplatelet therapy （DAPT）" treatment， and the combined group was given aspirin combined with clopidogrel "dual antiplatelet therapy （DAPT）" treatment+tirofiban combined with acupuncture and moxibustion treatment. The clinical efficacy， National Institutes of Health Stroke Scale（NIHSS） scores， Mini Mental State Examination （MMSE） scores， levels of hemorheological indicators， and adverse reactions between two groups were recorded and compared. Results：The total clinical effective rate of the combination group was 85.96%（49/57）， while that of the control group was 68.42%（39/57）， the combination group were obviously higher than the control group （P<0.05）； on the 7th day， the NIHSS score of the combined group was significantly lower than that of the control group（P<0.05）， while the MMSE score showed no difference compared with the control group（P>0.05）； on the 14th day， the NIHSS score of the combined group was significantly lower than that of the control group， while the MMSE score was significantly higher than that of the control group（P<0.05）. Compared with before treatment， the NIHSS scores in both groups on the 7th and 14th day decreased significantly， while the MMSE scores increased significantly（all P<0.05）. On the 7th and 14th day， the whole blood high shear viscosity， whole blood low shear viscosity， plasma viscosity， and red blood cell electrophoresis time in the combination group were significantly lower than those in the control group（all P<0.05）. Compared with before treatment， the whole blood high shear viscosity， whole blood low shear viscosity， plasma viscosity， and red blood cell electrophoresis time in the two groups on 7th and 14th day were significantly reduced in sequence（all P<0.05）. The total incidence of adverse reactions in the combination group was 8.77%， while in the control group it was 12.28%， there was no significant difference between the two groups （P>0.05）. Conclusion： Acupuncture and moxibustion combined with tirofiban has a significant effect on patients with acute progressive cerebral infarction， it can effectively reduce NIHSS score， improve MMSE score， and improve hemorheological indicators of patients with high drug safety.

参考文献/References:

[1] ZHANG W，XU L，YU Z，et al. Inhibition of the glycolysis prevents the cerebral infarction progression through decreasing the lactylation levels of LCP1[J]. Mol Biotechnol，2023，65（8）：1336-1345.
[2] HUANG H Y，LIN S Y，KATZ A J，et al. Effectiveness and safety of clopidogrel vs aspirin in elderly patients with ischemic stroke[J]. Mayo Clin Proc，2022，97（8）：1483-1492.
[3] LI Y，CUI R，FAN F，et al. The efficacy and safety of ischemic stroke therapies： an umbrella review[J]. Front Pharmacol，2022，13（1）：924747-924760.
[4] WEISS L J，DRAYSS M，MANUKJAN G，et al. Uncoupling of pla-telet granule release and integrin activation suggests GPⅡb /Ⅲa as a therapeutic target in COVID-19[J]. Blood Adv，2023，7（11）：2324-2338.
[5] TIAN W，ZHANG T，GAO Y，et al. Efficacy and safety assessment of urokinase plus tirofiban in acute cerebral infarction patients without clear criminal vessels[J]. Pak J Pharm Sci，2022，35（3）：878-883.
[6] LI B，ZHAO Q，DU Y，et al. Cerebral blood flow velocity modu-lation and clinical efficacy of acupuncture for posterior circulation infarction vertigo： a systematic review and meta-analysis[J]. Evid Based Complement Alternat Med，2022，2022（1）：3740856-3740872.
[7] 何树诺，韩晓伟，潘茜，等. 眼针调控转录激活因子6通路改善急性脑缺血再灌注损伤大鼠自噬的机制研究[J].针刺研究，2022，47（10）：859-865.
[8] 中华医学会神经病学分会，中华医学会神经病学分会脑血管病学组，彭斌，等. 中国急性缺血性脑卒中诊治指南2018[J]. 中华神经科杂志，2018，51（9）：666-682.
[9] SENERS P，BARON J C．Revisiting progressive stroke：incidence，predictors，pathophysiology，and management of unexplained early neurological deterioration following acute ischemic stroke[J]．J Neurol，2018，265（1）：216-225．
[10] 郑筱萸. 中国新药临床研究指导原则[M]. 北京：中国医药科技出版社，2002：99-104.
[11] JI X，TIAN L，YAO S，et al. A systematic review of body fluids biomarkers associated with early neurological deterioration follow-ing acute ischemic stroke[J]. Front Aging Neurosci，2022，14（1）：918473-918486.
[12] KAMAROVA M，BAIG S，PATEL H，et al. Antiplatelet use in ischemic stroke[J]. Ann Pharmacother，2022，56（10）：1159-1173.
[13] DUAN H，YUN H J，GENG X，et al. Branch atheromatous disease and treatment[J]. Brain Circ，2022，8（4）：169-171.
[14] YANG M，HUO X，MIAO Z，et al. Platelet glycoproteinⅡb/Ⅲa receptor inhibitor tirofiban in acute ischemic stroke[J]. Drugs，2019， 79（5）：515-529.
[15] LIU Q，LU X，YANG H，et al. Early tirofiban administration for patients with acute ischemic stroke treated with intravenous thrombolysis or bridging therapy： systematic review and meta-analysis[J]. Clin Neurol Neurosurg，2022，222（1）：107449-107460.
[16] ZHANG H，ZHENG L. Statistical analysis for efficacy of tirofiban combined with ozagrel in the treatment of progressive cerebral infarction patients out of thrombolytic therapy time window[J]. Clinics （Sao Paulo），2021，76（1）：e2728.
[17] WANG P，YIN X，YANG Z. Clinical efficacy and the influence of fibrinogen，homocysteine and prognosis in acute ischemic stroke patients treated with tirofiban plus TERVO stent thrombectomy[J]. Pak J Pharm Sci，2023，36（2）：653-658.
[18] 倪晨斐，李成，徐静艳. 醒脑开窍针刺法联合西医治疗急性前循环脑梗死的短期疗效观察[J]. 中国中医急症，2022，31（2）：323-326.
[19] 董春雪，于楠楠，丛珊，等. 三七通舒胶囊联合醒脑开窍针刺法治疗急性脑梗死疗效及神经保护机制[J]. 中成药，2022，44（5）：1718-1722.
[20] 徐文源，代优，郝继涛. 针灸辨证取穴治疗老年急性脑梗死的临床效果[J]. 中国老年学杂志，2022，42（20）：4931-4933.
[21] 陈光希，姚涛，何静，等. 醒脑开窍针刺法联合丁苯酞治疗急性基底节脑梗死的临床研究[J]. 中西医结合心脑血管病杂志，2022，20（13）：2449-2452.

相似文献/References:

[1]刘 杰,宋书凯.早期应用不同剂量替罗非班在急性ST段抬高型心肌梗死患者中的临床观察[J].天津医科大学学报,2017,23(01):59.
　LIU Jie,SONG Shu-kai.Clinical observation of early application of different doses of trofiban in patients with acute ST-segment elevation myocardial infarction[J].Journal of Tianjin Medical University,2017,23(03):59.

备注/Memo

备注/Memo:

基金项目 河北省卫生健康委员会资助项目（20220675）
作者简介 刘勇（1990-），男，主治医师，硕士在读，研究方向：脑血管病；通信作者：张美云，E-mail：zmy22202@aliyun.com。

常用功能

更新日期/Last Update: 2024-05-20